70 A formidable foe in the world of oncology, chondrosarcoma has long defied conventional treatments, leaving patients with advanced cases facing grim prospects. This malignant bone cancer, the second most common of its kind after osteosarcoma, strikes adults and the elderly with a vengeance, often resisting chemotherapy and radiotherapy. But a comprehensive review published in the International Journal of Molecular Sciences offers a glimmer of hope, unveiling fresh insights into the disease’s molecular underpinnings and spotlighting innovative therapies that could transform patient outcomes. Chondrosarcoma accounts for 20–30% of all malignant bone tumours, with its various subtypes presenting a complex tapestry of biological and genetic traits. The most prevalent form, conventional chondrosarcoma, often grows slowly and rarely spreads, allowing many patients to benefit from surgical resection. Yet, for those with high-grade, dedifferentiated, or metastatic variants, the prognosis darkens considerably due to the cancer’s stubborn resistance to standard treatments. This resistance stems from a dense cartilaginous matrix and poor vascularisation, which thwart drug delivery and radiation effectiveness, leaving clinicians scrambling for alternatives. Recent research has peeled back the layers of chondrosarcoma’s complexity, identifying key genetic mutations that drive its progression. Mutations in the IDH1 and IDH2 genes, found in 50-80% of central and dedifferentiated cases, disrupt cellular metabolism, producing an oncometabolite that fuels tumour growth. Other culprits, such as TP53 mutations and amplifications of the EPAS1 gene, which encodes HIF-2α, further escalate the disease’s aggression, particularly in high-grade forms. These discoveries have ignited efforts to develop targeted therapies, with drugs like ivosidenib, an IDH1 inhibitor, showing promise in early clinical trials by stabilising disease in over half of treated patients. Beyond genetics, the tumour microenvironment has emerged as a critical battleground. The review highlights how immune cells, such as macrophages, can either hinder or hasten tumour growth, depending on their type and distribution. This has spurred exploration into immunotherapies, including checkpoint inhibitors like pembrolizumab, which have yielded mixed but encouraging results in small patient cohorts. Meanwhile, antiangiogenic drugs such as pazopanib, which target blood vessel formation, have extended progression-free survival in some cases, hinting at a multi-pronged approach to tackling this elusive cancer. Preclinical models have also taken centre stage, with patient-derived xenografts and 3D organoids offering a closer mimicry of human disease than traditional cell lines. These advanced tools are accelerating drug testing, revealing new vulnerabilities like the SIRT1-HIF-2α axis, which could be exploited to enhance chemosensitivity. Epigenetic therapies, aiming to reverse abnormal gene silencing, are another avenue under scrutiny, though initial trials have yet to hit their mark. As chondrosarcoma’s rarity and heterogeneity pose ongoing challenges, the integration of multi-omic profiling, which combines genetic, molecular, and immune data, promises to refine patient stratification and tailor treatments more effectively. While no single cure has emerged, this wave of research signals a shift towards personalised medicine, offering renewed optimism for those battling this tenacious disease.